@PharmaThreads (@soixh37565262) 's Twitter Profile
@PharmaThreads

@soixh37565262

Risk-aware

ID: 1748641548961456128

calendar_today20-01-2024 09:40:24

45 Tweet

5 Followers

24 Following

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$BTC $MSTR this is screwed tommorow for earnings. Only thing worse for Saylor then this is if his name turns up in the Epstein files.

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$HIMS lawsuit will take more than 5 years . This case will be settled out before that. Meanwhile hims will continue to sell weight loss injections. No revenue is going to lose. Stop spreading garbage information about losing sales

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$MAAS Another overlooked angle: data. Huazhi Future combines compute power with big data and algorithm resources. That means MAAS can turn operational data into AI services. This is exactly the flywheel driving modern AI companies. $PLTR $SNOW $ASTS $ONDS

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$HIMS A +83% bounce at strong support. You are also above 24-25 which was a " big resistance" A bounce has potential to take us 43. Thats the next target. Everyone hated it at 15.

$HIMS A +83% bounce at strong support.    

You are also above 24-25 which was a " big resistance" 

A bounce has potential to take us 43.   Thats the next target.    

Everyone hated it at 15.
@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

Novo's CagriSema failure confirms the bull case for $VKTX. VK2735 uses the winning GLP-1/GIP mechanism. With Phase 3 starting and strong cash, shorts are in trouble. Do you own the winning drug class?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$BCRX has put investors through a lot, but what’s coming is rightfully ours. Buying Astria makes this a prime takeover target as navenibart nears revenue generation. I’m betting on $22.75+. What are your thoughts on Charlie?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

Selling $ONDS while drone demand peaks is mind-blowing. With price targets at 25 and revenue expected to hit 375M, this ramp will be amazing. Profitability may even arrive early. Do you agree on the timeline?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

I have 3.1M shares of $NWBO and remain bullish after 11 years, but the MAA delay is concerning. Management's silence and ongoing dilution while the price drops are scary. What do you think of the delay?

I have 3.1M shares of $NWBO and remain bullish after 11 years, but the MAA delay is concerning. Management's silence and ongoing dilution while the price drops are scary. What do you think of the delay?
@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$MAAS is rethinking energy delivery through AI forecasting, dynamic dispatch, and mobile charging. This synchronized approach creates real long-term value. What do you think of this model?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

I have 3.1M shares in $NWBO, but the MAA process is taking five times longer than expected. Management’s silence and constant dilution as the price crashes is scary. Are you worried about the delay?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$ASTS isn't building Bluebirds to stay grounded or making MOUs to waste time. They aim to connect the unconnected and build a global powerhouse. After four years, success is near. Do you agree?

$ASTS isn't building Bluebirds to stay grounded or making MOUs to waste time. They aim to connect the unconnected and build a global powerhouse. After four years, success is near. Do you agree?
@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$ONDS options price an 8.75% move by March 27, far below the 12.62% average. Traders may be missing volatility after recent 19.06% and 25.07% swings. Do you expect a bigger move?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$MAAS just released its MCR whitepaper, evolving from a simple charger to a mobile energy node. It is a paradigm shift where chargers find cars. What do you think of this shift?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$MAAS Key takeaway: MCR combines distributed storage with VPP nodes. This unlocks a secondary revenue engine beyond simple charging. What do you think about this dual model?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$MAAS has released its MCR whitepaper. A key highlight is that the technology complements rather than replaces traditional charging. Have you reviewed the new whitepaper yet?

$MAAS has released its MCR whitepaper. A key highlight is that the technology complements rather than replaces traditional charging. Have you reviewed the new whitepaper yet?
@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

MCRs are distributed energy storage nodes that integrate into the grid rather than just charging. $MAAS $ONDS $SPRT $SNDK. How do you see these nodes impacting grid stability?

MCRs are distributed energy storage nodes that integrate into the grid rather than just charging. $MAAS $ONDS $SPRT $SNDK. How do you see these nodes impacting grid stability?
@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$NVAX Shah’s half truths are tired. Sanofi partnership absolutely saved Novavax—avoided bankruptcy, extended runway for Pfizer tie-up, cut costs, and built low-cost high-margin profits. It’s underperformed expectations but who isn’t struggling right now?

@PharmaThreads (@soixh37565262) 's Twitter Profile Photo

$ONDS We can still make a run at 11 this week—unlikely to hold long with big options pressure, but I’d rather see steady upside in the 10s and push 11 next week. 9s is now consolidation. Either way, shorts are screwed.